Johnson & Johnson Stops HIV Vaccine Trial In African Women

Johnson & Johnson JNJ and a consortium of global partners announced results from the primary analysis of a Phase 2b HIV vaccine trial, Imbokodo study.
Data showed that the investigational HIV vaccine regimen did not provide sufficient protection against HIV infection in a population of young women in sub-Saharan Africa at high risk of acquiring HIV. The vaccine candidate showed a favorable safety profile with no serious adverse events.
Based on these results, the Imbokodo study will not continue, while further study analysis is ongoing.
In parallel to the Phase 2b Imbokodo HIV vaccine trial, Janssen sponsored the ongoing Phase 3 Mosaico study. The study will test the safety and efficacy of a different composition of the HIV vaccine regimen among men who have sex with men (MSM) and transgender individuals.
This study is being conducted in the Americas and Europe, where different strains of HIV are circulating.
Price Action: JNJ stock is down 0.09% at $173.50 during the premarket session on the last check Tuesday.